会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB)
    • ERK1 / ERK2磷酸化比例的阿尔茨海默病特异性改变 - 阿尔茨海默病特异性分子生物标志物(ADSMB)
    • US20080221042A1
    • 2008-09-11
    • US12078857
    • 2008-04-07
    • Tapan Kumar KhanDaniel L. Alkon
    • Tapan Kumar KhanDaniel L. Alkon
    • A61K38/08C12Q1/02A61P25/28
    • G01N33/6896A61K38/043A61K38/095A61K38/105A61K38/2207A61K38/4833G01N2800/2821G01N2800/52
    • The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the Alzheimer's Disease-specific molecular biomarkers disclosed herein.
    • 本发明涉及诊断阿尔茨海默病的方法以及确认受试者中是否存在阿尔茨海默氏病的方法。 本发明还涉及通过使非阿尔茨海默病细胞与淀粉状蛋白β肽接触,用蛋白激酶C激活剂刺激细胞,使细胞与测试化合物接触来鉴定用于治疗阿尔茨海默病的铅化合物的方法, 并确定阿尔茨海默氏病特异性分子生物标志物的价值。 本发明还涉及通过检测用蛋白激酶C激活剂刺激后细胞中特异性磷酸化MAP激酶蛋白的比例变化来诊断受试者中的阿尔茨海默氏病的方法。 本文公开的阿尔茨海默病特异性分子生物标志物可用于诊断阿尔茨海默氏病,监测受试者中阿尔茨海默氏病的进展和用于鉴定用于治疗或预防阿尔茨海默氏病的化合物的筛选方法。 本发明还涉及包含用于使用本文公开的阿尔茨海默病特异性分子生物标志物来检测和诊断阿尔茨海默氏病或​​不存在的试剂的试剂盒。
    • 9. 发明授权
    • Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
    • Erk1 / Erk2磷酸化比例的阿尔茨海默病特异性改变
    • US07595167B2
    • 2009-09-29
    • US11246524
    • 2005-10-11
    • Tapan Kumar KhanDaniel L. Alkon
    • Tapan Kumar KhanDaniel L. Alkon
    • G01N33/567G01N33/561
    • G01N33/6896G01N2800/2821
    • The present invention is directed to a method of diagnosing Alzheimer's disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's disease, monitoring the progression of Alzheimer's disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's disease. The invention is also directed to kits containing reagents for the detection and diagnosis of Alzheimer's disease using the Alzheimer's disease-specific molecular biomarkers disclosed herein.
    • 本发明涉及通过检测用蛋白激酶C激活剂刺激后细胞中特异性磷酸化MAP激酶蛋白比例的变化来诊断受试者中的阿尔茨海默氏病的方法。 本文公开的阿尔茨海默氏病特异性分子生物标志物可用于诊断阿尔茨海默氏病,监测受试者中阿尔茨海默氏病的进展和用于鉴定用于治疗或预防阿尔茨海默氏病的化合物的筛选方法。 本发明还涉及使用本文公开的阿尔茨海默氏病特异性分子生物标志物的含有用于检测和诊断阿尔茨海默病的试剂的试剂盒。
    • 10. 发明申请
    • Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
    • Erk1 / Erk2磷酸化比例的阿尔茨海默病特异性改变 - 阿尔茨海默病特异性分子生物标志物(Adsmb)
    • US20090029873A1
    • 2009-01-29
    • US12083056
    • 2006-09-25
    • Tapan Kumar KhanDaniel L. Alkon
    • Tapan Kumar KhanDaniel L. Alkon
    • C40B30/06C12Q1/02C12Q1/48G01N33/573
    • G01N33/6896G01N2333/4709G01N2333/912G01N2800/2821
    • The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the Alzheimer's Disease-specific molecular biomarkers disclosed herein.
    • 本发明涉及诊断阿尔茨海默病的方法以及确认受试者中是否存在阿尔茨海默氏病的方法。 本发明还涉及通过使非阿尔茨海默病细胞与淀粉状蛋白β肽接触,用蛋白激酶C激活剂刺激细胞,使细胞与测试化合物接触来鉴定用于治疗阿尔茨海默病的铅化合物的方法, 并确定阿尔茨海默氏病特异性分子生物标志物的价值。 本发明还涉及通过检测用蛋白激酶C激活剂刺激后细胞中特异性磷酸化MAP激酶蛋白的比例变化来诊断受试者中的阿尔茨海默氏病的方法。 本文公开的阿尔茨海默病特异性分子生物标志物可用于诊断阿尔茨海默氏病,监测受试者中阿尔茨海默氏病的进展和用于鉴定用于治疗或预防阿尔茨海默氏病的化合物的筛选方法。 本发明还涉及包含用于使用本文公开的阿尔茨海默病特异性分子生物标志物来检测和诊断阿尔茨海默氏病或​​不存在的试剂的试剂盒。